Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6272-6285

  Hsu, Ya Ting ^a   Gu, Fei ^a   Huang, Yi Wen ^e   Liu, Joseph ^a   Ruan, Jianhua ^d   Huang, Rui Lan ^f,g   Wang, Chiou Miin ^a   Chen, Chun Liang ^a   Jadhav, Rohit R ^a   Lai, Hung Cheng ^f,g,h   Mutch, David G ⁱ   Goodfellow, Paul J ^j   Thompson, Ian M ^b,c   Kirma, Nameer B ^a,c   Huang, Tim Hui Ming ^a,c  

^a University of Texas Health Science Center   (United States)

^b Department of Urology ^*  (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d One UTSA Circle   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^g Cancer Stem Cells   (Taiwan)

^h NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

ⁱ Washington University in St Louis School of Medicine   (United States)

^j OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELL ADHESION MOLECULE;

ARTICLE; BIOINFORMATICS; BMP GENE; BMP1 GENE; BMP2 GENE; BMP3 GENE; BMP4 GENE; BMP7 GENE; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; ENDOMETRIUM CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENE SEQUENCE; GENE SILENCING; GENETIC CORRELATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANTIGENS, NEOPLASM; BASE SEQUENCE; BONE MORPHOGENETIC PROTEINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; SURVIVAL; TRANSCRIPTIONAL ACTIVATION;

EID: 84888082619     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1734     Document Type: Article

References (66)

1. Sorosky JI. Endometrial cancer. Obstet Gynecol 2012;120:383-97.
2. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17:85-103. (Pubitemid 14176295)
3. Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 2006;102:480-8. (Pubitemid 44353642)
4. Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995;59:221-5.
5. Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2010;2:419-47.
6. Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, et al. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol 2010;117:239-47.
7. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 2002;94:2941-52. (Pubitemid 34547694)
8. Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, et al. Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res 2011;71:1752-62.
9. de Assis S, Warri A, Cruz MI, Laja O, Tian Y, Zhang B, et al. High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring. Nat Commun 2012;3:1053.
10. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
11. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
12. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011;21:502-17.
13. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res 2007;67:4545-9. (Pubitemid 46910155)
14. Hsiao SH, Huang TH, Leu YW. Excavating relics of DNA methylation changes during the development of neoplasia. Semin Cancer Biol 2009;19:198-208.
15. Szyf M. The role of DNA hypermethylation and demethylation in cancer and cancer therapy. Curr Oncol 2008;15:72-5.
16. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004;211:133-43. (Pubitemid 38824627)
17. Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumour suppressor genes in multiple myeloma. Blood 2013;122:219-26.
18. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 2013;98:2811-21.
19. De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, et al. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. Br J Cancer 2013;108:1368-77.
20. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011;11:726-34.
21. Belkhiri A, El-Rifai W. 5-Methylcytosine hydroxylation-mediated LINE-1 hypomethylation: a novel mechanism of proto-oncogenes activation in colorectal cancer? Gut. 2013 Jun. 27. [Epub ahead of print].
22. Kim R, Kulkarni P, Hannenhalli S. Derepression of Cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer 2013;13:144.
23. Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS, et al. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer 2012;11:27.
24. Yacqub-Usman K, Duong CV, Clayton RN, Farrell WE. Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression. Endocrinology 2012;153:3603-12.
25. Hashida Y, Nemoto Y, Imajoh M, Murakami M, Taniguchi A, Komatsu N, et al. Promoter methylation of the bone morphogenetic protein 6 gene in multiple myeloma. Oncol Rep 2012;27:825-30.
26. Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, et al. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep 2008;20:1265-8.
27. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006;25:2666-73.
28. Yang ZJ, Liu FX, Yang YS, Yang X, Zhu GX. Expression of bonemorphogenetic protein 2 and tumor necrosis factor alpha correlates with bone metastases in bladder urothelial carcinoma. Ann Diagn Pathol 2013;17:51-3.
29. Guo X, Xiong L, Zou L, Zhao J. Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 2012;18:635-40.
30. Xu G, Tang S, Yang J, Chen K, Kang J, Zhao G, et al. BMP7 expression in esophageal squamous cell carcinoma and its potential role in modulating metastasis. Dig Dis Sci 2013;58:1871-9
31. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58. (Pubitemid 39093020)
32. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010;31:1913-21.
33. De La Garza EM, Binkley PA, Ganapathy M, Krishnegowda NK, Tekmal RR, Schenken RS, et al. Raf-1, a potential therapeutic target, mediates early steps in endometriosis lesion development by endometrial epithelial and stromal cells. Endocrinology 2012;153:3911-21.
34. Hsu PY, Hsu HK, Singer GA, Yan PS, Rodriguez BA, Liu JC, et al. Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res 2010;20:733-44.
35. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, et al. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci U S A 2008;105:4844-9. (Pubitemid 351753834)
36. Robinson MD, Stirzaker C, Statham AL, Coolen MW, Song JZ, Nair SS, et al. Evaluation of affinity-based genome-wide DNA methylation data: effects of CpG density, amplification bias, and copy number variation. Genome Res 2010;20:1719-29.
37. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010;38:391-9.
38. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
39. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005;96:403-8. (Pubitemid 41179741)
40. Huang SS, Fraenkel E. Integrating proteomic, transcriptional, and interactome data reveals hidden components of signaling and regulatory networks. Sci Signal 2009;2:ra40.
41. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human proteinreference database-2009 update. Nucleic Acids Res 2009;37:D767-72.
42. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52. (Pubitemid 351442996)
43. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42. (Pubitemid 43278296)
44. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 2007;102:829-39. (Pubitemid 350036923)
45. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
46. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
47. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007;5:283-93. (Pubitemid 46569779)
48. Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Distefano M, D'Andrea G, et al. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int J Cancer 1994;56:26-30. (Pubitemid 24044788)
49. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013;41:3973-85.
50. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006;66:3541-9.
51. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011;27:347-76.
52. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
53. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011;193:23-40.
54. Beltran M, Puig I, Pena C, Garcia JM, Alvarez AB, Pena R, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev 2008;22:756-69. (Pubitemid 351439107)
55. Denzel S, Maetzel D, Mack B, Eggert C, Barr G, Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009;9:402.
56. Bandyopadhyay A, Yadav PS, Prashar P. BMP signaling in development and diseases: a pharmacological perspective. Biochem Pharmacol 2013;85:857-64.
57. Chen A, Wang D, Liu X, He S, Yu Z, Wang J. Inhibitory effect of BMP-2 on the proliferation of breast cancer cells. Mol Med Rep 2012;6:615-20.
58. Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN, et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2009;2:4.
59. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 2010;316:24-37.
60. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 2011;71:5194-203.
61. Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther 2004;3:1058-9. (Pubitemid 41350984)
62. Al Moustafa AE, Achkhar A, Yasmeen A. EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci 2012;4:671-84.
63. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006;100:101-6. (Pubitemid 41815057)
64. Niikura H, Sasano H, Matsunaga G, Watanabe K, Ito K, Sato S, et al. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 1995;26:892-6.
65. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71.
66. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73. (Pubitemid 46622055)